The 2026 SNMMI annual meeting featured a genitourinary radiotherapeutics session and a presentation by Dr. Yalda Nikanpour ...

Dr. Pepin concluded her presentation discussing a secondary analysis of the VISION trial assessing the impact of external ...

Higher baseline PET SUVmean and cycle 1 whole body tumor volume absorbed dose are associated with a more favorable PSA response following early cycles of 177 Lu-PSMA, as well as after therapy ...

Zachary Klaassen discusses hydrogel spacer placement and resident education, drawing on approximately 250 Barrigel® procedures performed since FDA clearance in 2022. He describes ...

Overall, 1,855 male patients across all disease stages, with 179 (9.6%) reported deaths and median overall survival follow-up ...

The 2026 ASCO annual meeting featured a plenary session and a discussant presentation by Dr. Jeremie Calais discussing two ...

(UroToday.com) The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session and a presentation by Molly Wynveen discussing survival in Veterans with metastatic ...

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...

Finally, current quality-of-life tools do not fully capture the patient experience. Emerging approaches incorporating patient ...

The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session, including a presentation by Dr. Surekha Yadav discussing longitudinal outcomes of PSMA PET/CT-detected bone ...

(UroToday.com) The 2026 SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Akshay Bedmutha discussing the safety and efficacy of rechallenge PSMA ...

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. David Cade presented LUTEON, an ongoing phase III trial ...